Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: GlobeNewswire
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Titles and PresentersPresentation DetailsTitle Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900Presenter Gerald Falchook, MD Sarah Cannon Research Institute at HealthOne Denver, CO, United States.Session Poster Session APoster Number LB-A019Session Date / Time October 23, 2025 12:30 – 4 pm ETTitle NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, potently inhibits tumor growth in FAT1 mutated xeno
Show less
Read more
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCGlobeNewswire
- Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]Yahoo! Finance
- CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswire
NVCT
Earnings
- 8/5/25 - Miss
NVCT
Analyst Actions
- 12/3/25 - HC Wainwright
NVCT
Sec Filings
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- NVCT's page on the SEC website